Category: Tandem Diabetes Care Inc.
Tandem Diabetes is taking orders for its new t:flex insulin pump, 4 months after FDA officials cleared the new device.
Here's a look at some of the top legal news stories for medical device companies this week: Diabetes: Tandem plans $60m offering; OrthoSensor pulls in $17m funding round; EndoChoice raises $57m for Fuse endoscope; InspireMD looks to raise $14m for CGuard stent launch
Tandem Diabetes Care closes on a public offering valued at roughly $60 million.
Tandem Diabetes Care (NSDQ:TNDM) this week said it closed on a previously announced public offering valued at around $60 million.
Tandem Diabetes Care says it's planning a 5.25-million-share offering worth $60 million for its line of insulin pumps.
Tandem Diabetes Care (NSDQ:TNDM) said last week that it's planning a $60 million public offering for its line of insulin pumps.
Tandem Diabetes shares gain today after the FDA grants 510(k) clearance for the Tandem's t:flex insulin pump, which has a larger reservoir than its t:slim predecessor.
Tandem Diabetes teams with a non-profit to boost access to a diabetes data through an open-source software platform.
Tandem Diabetes' shares lose about 7% in morning trading after the company widens its insulin cartridge recall to include older units.